Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Return on Capital Employed (2016 - 2025)

International Stem Cell (ISCO) has disclosed Return on Capital Employed for 15 consecutive years, with 0.13% as the latest value for Q2 2025.

  • On a quarterly basis, Return on Capital Employed rose 107.0% to 0.13% in Q2 2025 year-over-year; TTM through Jun 2025 was 0.13%, a 107.0% increase, with the full-year FY2024 number at 0.11%, up 143.0% from a year prior.
  • Return on Capital Employed was 0.13% for Q2 2025 at International Stem Cell, up from 0.36% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.13% in Q2 2025 to a low of 3.22% in Q1 2022.
  • A 5-year average of 1.27% and a median of 0.95% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -223bps in 2021, then surged 271bps in 2023.
  • International Stem Cell's Return on Capital Employed stood at 2.92% in 2021, then soared by 86bps to 0.4% in 2022, then plummeted by -140bps to 0.97% in 2023, then soared by 86bps to 0.14% in 2024, then increased by 3bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Return on Capital Employed are 0.13% (Q2 2025), 0.36% (Q1 2025), and 0.14% (Q4 2024).